FDA Warns Against Compounded Moxifloxacin Injections
FDA received case reports of TASS (Toxic Anterior Segment Syndrome) following intraocular administration of compounded drugs using moxifloxacin as a bulk drug substance, as well as reports associated with the intraocular administration of repackaged and/or diluted FDA-approved moxifloxacin drugs.
Dr. David Hussong explains the FDA’s recent alert to health care professionals of risks associated with intraocular use of compounded moxifloxacin.
Learn more about this on the FDA website through the link below:
- Environmental Monitoring Analyses: Early Warning Opportunities for Sterile Compounders - July 23, 2021
- The Mindset of Quality Operations - June 24, 2021
- Central Drug Compounding & Wellness Recommends Eagle Plates - April 16, 2021